{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:49:34Z","timestamp":1790401774399,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"am","delay-in-days":295,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA262577"],"award-info":[{"award-number":["R01CA262577"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0339"],"award-info":[{"award-number":["W81XWH-21-1-0339"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0234"],"award-info":[{"award-number":["W81XWH-21-1-0234"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-19-1-0554"],"award-info":[{"award-number":["W81XWH-19-1-0554"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["404527522"],"award-info":[{"award-number":["404527522"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007886","name":"Dana-Farber Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007886","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001068","name":"Dana Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001068","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006691","name":"Harvard Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001463","name":"American Society of Nephrology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001255","name":"National Cancer Coalition","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["5P30CA006516-56"],"award-info":[{"award-number":["5P30CA006516-56"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R03CA230944"],"award-info":[{"award-number":["R03CA230944"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA251555"],"award-info":[{"award-number":["R01CA251555"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.canlet.2025.217984","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T21:24:06Z","timestamp":1755552246000},"page":"217984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress"],"prefix":"10.1016","volume":"633","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-4903","authenticated-orcid":false,"given":"Akash","family":"Sabarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6708-9922","authenticated-orcid":false,"given":"Marc","family":"Machaalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxminarayan","family":"Rawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3490-8477","authenticated-orcid":false,"given":"Johannes","family":"Wedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Tabasum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuru","family":"Sasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josie","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Eid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2315-8422","authenticated-orcid":false,"given":"Karl","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Stephen","family":"Hodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwo-Shu","family":"Mary Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murugabaskar","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumitro","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217984_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-023-01745-7","article-title":"Liquid biopsy at the frontier in renal cell carcinoma: recent analysis of techniques and clinical application","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-023-01911-x","article-title":"Evolution of cell therapy for renal cell carcinoma","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2025.217984_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.217984_bib5","doi-asserted-by":"crossref","first-page":"75478","DOI":"10.18632\/oncotarget.20796","article-title":"Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2025.217984_bib6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/annonc\/mds463","article-title":"c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma","volume":"24","author":"Gibney","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217984_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/PPO.0b013e31829e3c9a","article-title":"Targeting the hepatocyte growth factor\/c-Met signaling pathway in renal cell carcinoma","volume":"19","author":"Harshman","year":"2013","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2025.217984_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00152","article-title":"Targeting the HGF\/MET axis in cancer therapy: challenges in resistance and opportunities for improvement","volume":"8","author":"Huang","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib10","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1128\/MCB.25.21.9632-9645.2005","article-title":"Met\/hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation","volume":"25","author":"Abella","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105233","article-title":"Knockout of c-Cbl\/Cbl-b slows c-Met trafficking resulting in enhanced signaling in corneal epithelial cells","volume":"299","author":"Tarvestad-Laise","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.217984_bib12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/carcin\/bgw015","article-title":"Regulation of the MET oncogene: molecular mechanisms","volume":"37","author":"Zhang","year":"2016","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2025.217984_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cells7030022","article-title":"Receptor tyrosine kinase ubiquitination and De-Ubiquitination in signal transduction and receptor trafficking","volume":"7","author":"Critchley","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2025.217984_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1128\/MCB.17.2.799","article-title":"Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway","volume":"17","author":"Jeffers","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217984_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1634\/theoncologist.2017-0335","article-title":"Management of adverse events associated with cabozantinib therapy in renal cell carcinoma","volume":"23","author":"Schmidinger","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.217984_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41392-022-01168-8","article-title":"Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective","volume":"7","author":"Yang","year":"2022","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.217984_bib18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12943-018-0801-5","article-title":"Advances in studies of tyrosine kinase inhibitors and their acquired resistance","volume":"17","author":"Jiao","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41389-018-0116-9","article-title":"Activation of c-Met in cancer cells mediates growth-promoting signals against oxidative stress through Nrf2-HO-1","volume":"8","author":"Chakraborty","year":"2019","journal-title":"Oncogenesis"},{"key":"10.1016\/j.canlet.2025.217984_bib20","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.3390\/cancers15112998","article-title":"The role of MET in resistance to EGFR inhibition in NSCLC: a review of mechanisms and treatment implications","volume":"15","author":"Feldt","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.217984_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2025.217984_bib22","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bjc.2015.237","article-title":"Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma","volume":"113","author":"Yu","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/carcin\/bgab126","article-title":"A combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation","volume":"43","author":"Sabarwal","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2025.217984_bib24","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrc3847","article-title":"The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer","volume":"14","author":"Graham","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib25","first-page":"2726","article-title":"Function of Axl receptor tyrosine kinase in non-small cell lung cancer","volume":"15","author":"Zhang","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2025.217984_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/cells9010247","article-title":"AXL controls directed migration of mesenchymal triple-negative breast cancer cells","volume":"9","author":"Zajac","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2025.217984_bib27","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1158\/1078-0432.CCR-14-2648","article-title":"AXL is a logical molecular target in head and neck squamous cell carcinoma","volume":"21","author":"Brand","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217984_bib28","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/ijms22189953","article-title":"Therapeutic targeting of the Gas6\/Axl signaling pathway in cancer","volume":"22","author":"Tanaka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2025.217984_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2024596118","article-title":"The GAS6-AXL signaling pathway triggers actin remodeling that drives membrane ruffling, macropinocytosis, and cancer-cell invasion","volume":"118","author":"Zd\u017calik-Bielecka","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2025.217984_bib30","doi-asserted-by":"crossref","first-page":"15397","DOI":"10.1074\/jbc.RA118.003063","article-title":"HGF-induced formation of the MET\u2013AXL\u2013ELMO2\u2013DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell migration and invasion","volume":"293","author":"Li","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.217984_bib31","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3892\/or.2017.5482","article-title":"AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis","volume":"37","author":"Choi","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2025.217984_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41392-024-02121-7","article-title":"AXL signaling in cancer: from molecular insights to targeted therapies","volume":"10","author":"Yadav","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2025.217984_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib34","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.canlet.2008.04.017","article-title":"Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia","volume":"268","author":"Hong","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217984_bib35","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/0008-5472.CAN-14-0294","article-title":"AXL mediates resistance to cetuximab therapy","volume":"74","author":"Brand","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2025.217984_bib36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-9167-9_8","article-title":"Isolation of tumor-infiltrating lymphocytes by ficoll-paque density gradient centrifugation","volume":"1960","author":"Tan","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib37","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1182\/blood.V96.12.3801","article-title":"Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo","volume":"96","author":"Melter","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2025.217984_bib38","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217984_bib39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217984_bib40","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","article-title":"RNA-SeQC: RNA-seq metrics for quality control and process optimization","volume":"28","author":"DeLuca","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217984_bib41","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib42","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2025.217984_bib43","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS"},{"key":"10.1016\/j.canlet.2025.217984_bib44","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-Seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib45","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217984_bib46","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/bioinformatics\/btp328","article-title":"Rtracklayer: an R package for interfacing with genome browsers","volume":"25","author":"Lawrence","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.canlet.2025.217984_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib48","doi-asserted-by":"crossref","first-page":"W187","DOI":"10.1093\/nar\/gku365","article-title":"deepTools: a flexible platform for exploring deep-sequencing data","volume":"42","author":"Ram\u00edrez","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2025.217984_bib49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neo.2022.01.001","article-title":"UALCAN: an update to the integrated cancer data analysis platform","volume":"25","author":"Chandrashekar","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2025.217984_bib50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","article-title":"UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses","volume":"19","author":"Chandrashekar","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2025.217984_bib51","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrc1893","article-title":"Drug penetration in solid tumours","volume":"6","author":"Minchinton","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.1211","article-title":"Tumor drug penetration measurements could be the neglected piece of the personalized cancer treatment puzzle","volume":"106","author":"Bartelink","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2025.217984_bib53","doi-asserted-by":"crossref","first-page":"L56","DOI":"10.1152\/ajplung.00417.2012","article-title":"Lipopolysaccharide-induced phosphorylation of c-Met tyrosine residue 1003 regulates c-Met intracellular trafficking and lung epithelial barrier function","volume":"305","author":"Zhao","year":"2013","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.canlet.2025.217984_bib54","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.bbrc.2018.09.127","article-title":"Disproportionately high levels of HGF induce the degradation of the c-met receptor through the proteasomal degradation pathway","volume":"505","author":"Lee","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2025.217984_bib55","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1096\/fj.11-197723","article-title":"Met degradation: more than one stone to shoot a receptor down","volume":"26","author":"Lefebvre","year":"2012","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2025.217984_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129650","article-title":"The c-MET oncoprotein: function, mechanisms of degradation and its targeting by novel anti-cancer agents","volume":"1864","author":"Park","year":"2020","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.canlet.2025.217984_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153777","article-title":"Tyrosine kinase inhibitors in the treatment of metastasised renal cell carcinoma-future or the past?","volume":"14","author":"Michaelis","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.217984_bib58","first-page":"507","article-title":"Treatment of renal cell carcinoma: current status and future directions","volume":"67","author":"Barata","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2025.217984_bib59","first-page":"141","article-title":"Drug resistance and combating drug resistance in cancer","volume":"2","author":"Wang","year":"2019","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.canlet.2025.217984_bib60","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217984_bib61","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217984_bib62","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1038\/onc.2015.343","article-title":"Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217984_bib63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nrc.2017.93","article-title":"Transport of drugs from blood vessels to tumour tissue","volume":"17","author":"Dewhirst","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2025.217984_bib64","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2025.217984_bib65","doi-asserted-by":"crossref","first-page":"16103","DOI":"10.1073\/pnas.1314385110","article-title":"Cell motility and drug gradients in the emergence of resistance to chemotherapy","volume":"110","author":"Wu","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2025.217984_bib66","volume":"105","author":"Laimon","year":"2025"},{"key":"10.1016\/j.canlet.2025.217984_bib67","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.canlet.2025.217984_bib68","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16568","article-title":"Potential role of dose escalation in overcoming acquired resistance to cabozantinib in metastatic renal cell carcinoma (mRCC)","volume":"39","author":"Sharma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217984_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102945","article-title":"A novel combination therapy with Cabozantinib and Honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress","volume":"68","author":"Rawat","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib70","doi-asserted-by":"crossref","first-page":"6239","DOI":"10.1158\/1078-0432.CCR-17-1284","article-title":"Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer","volume":"23","author":"Sen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217984_bib71","doi-asserted-by":"crossref","first-page":"v172","DOI":"10.1093\/annonc\/mdz244.022","article-title":"460P - a phase Ia\/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumours","volume":"30","author":"Sarantopoulos","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217984_bib72","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12967-021-03042-7","article-title":"SLC7A11 regulated by NRF2 modulates esophageal squamous cell carcinoma radiosensitivity by inhibiting ferroptosis","volume":"19","author":"Feng","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217984_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217726","article-title":"SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis","volume":"623","author":"Zhang","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217984_bib74","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1074\/jbc.M114.612689","article-title":"Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression","volume":"290","author":"Balan","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2025.217984_bib75","article-title":"AXL targeting restores PD-1 blockade sensitivity of STK11\/LKB1 mutant NSCLC through expansion of TCF1(+) CD8 T cells","volume":"3","author":"Li","year":"2022","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2025.217984_bib76","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/onc.2012.396","article-title":"HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors","volume":"32","author":"Gusenbauer","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217984_bib77","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41388-022-02400-z","article-title":"Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors","volume":"41","author":"Dieter","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217984_bib78","doi-asserted-by":"crossref","first-page":"13373","DOI":"10.1073\/pnas.1404848111","article-title":"Direct regulation of GAS6\/AXL signaling by HIF promotes renal metastasis through SRC and MET","volume":"111","author":"Rankin","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2025.217984_bib79","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/onc.2010.504","article-title":"AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma","volume":"30","author":"Xu","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217984_bib80","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2025.217984_bib81","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ebiom.2018.02.001","article-title":"Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive non-smallcell lung cancer associated with poor prognosis","volume":"29","author":"Karachaliou","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.canlet.2025.217984_bib82","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.canlet.2025.217984_bib83","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2159-8290.CD-15-0933","article-title":"Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance","volume":"6","author":"Miller","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217984_bib84","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217984_bib85","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1615\/CritRevOncog.v16.i1-2.60","article-title":"TAM receptors in leukemia: expression, signaling, and therapeutic implications","volume":"16","author":"Brand\u00e3o","year":"2011","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.canlet.2025.217984_bib86","first-page":"15","article-title":"The effect of oxidative phosphorylation on cancer drug resistance","author":"Zhao","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2025.217984_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216705","article-title":"Cancer resistance and metastasis are maintained through oxidative phosphorylation","volume":"587","author":"Uslu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217984_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101953","article-title":"Reactive oxygen species produced by altered tumor metabolism impacts cancer stem cell maintenance","volume":"44","author":"Tuy","year":"2021","journal-title":"Redox Biol."},{"key":"10.1016\/j.canlet.2025.217984_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/1958174","article-title":"The Nrf2\/HO-1 axis in cancer cell growth and chemoresistance","volume":"2016","author":"Furfaro","year":"2016","journal-title":"Oxid. Med. Cell. Longev."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525005543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:01:01Z","timestamp":1772809261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525005543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":89,"alternative-id":["S0304383525005543"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217984","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"217984"}}